Millendo Therapeutics (NASDAQ:MLND) and Zynerba Pharmaceuticals (NASDAQ:ZYNE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings. Analyst Recommendations This is a breakdown of recent ratings and recommmendations for Millendo Therapeutics and […]

by

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaqs use of your personal data can be found in our Privacy and Cookies Notice): To allow you to personalize the Mondaq websites you are visiting to show content (“Content”) relevant […]

by

The research report published by Zion Market Research, “Cannabis Edibles Market by Type (Solid Edibles, Topical Edibles, Inhalation, and Liquid Edibles), by Preparation (Cannabidiol and Tetrahydrocannabinol), and by Application (Cancer, Epilepsy, Arthritis, Multiple Sclerosis, Alzheimer’s, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025” provides complete outline is crystal clear penned down in the […]

by

The research report published by Zion Market Research, “Cannabidiol Products Market by Application (Food Beverages, Pharmaceuticals, Cosmetics, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025” provides complete outline is crystal clear penned down in the global Cannabidiol Products Market research report such that not only an unskilled individual but also a professional can […]

by

SG Americas Securities LLC acquired a new position in shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 15,473 shares of the company’s stock, valued at approximately $210,000. SG Americas Securities LLC owned approximately 0.07% of Zynerba […]

by

This article was originally published on StrategicLiving.com Jump on any wellness-related website and you will find glowing accolades for CBD oil. Along with the accolades, you will find references to various studies that attempt to prove the point and further entice you to make a purchase. The issue, at least for me, is that there […]

by

JERUSALEM, Sept. 16, 2019 /PRNewswire/ — Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that two posters in support of the Company’s Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented at the upcoming International Congress of Parkinson’s and Movement Disorder Society (MDS 2019) being held from September 22-26, 2019 in Nice, […]

by

JERUSALEM, Sept. 16, 2019 /PRNewswire/ — Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that two posters in support of the Company’s Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented at the upcoming International Congress of Parkinson’s and Movement Disorder Society (MDS 2019) being held from September 22-26, 2019 in Nice, […]

by

By Benedette Cuffari, M.Sc.Reviewed by Dr. Jennifer Logan, MD, MPH To date, over 545 different compounds have been identified and isolated from the Cannabis sativa L. (Cannabaceae) plant, of which include over 100 different cannabinoids. These compounds differ greatly in their chemical structure; thus, consumption of the cannabis plant can induce a wide range of […]

by

Zynerba Pharmaceuticals (NASDAQ: ZYNE) stock retreated on Wednesday after serious adverse events in phase 2 clinical trial of transdermal cannabidiol gel, Zygel. The shares were weak lately as the stock has fallen over 17% in the past month and over 31% in the past three months. Investors remained concerned about the company’s future and raised […]

by

JERUSALEM, Sept. 3, 2019 /PRNewswire/ — Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces that Company management will participate at the following upcoming investment conferences in September. HC Wainwright 21st Annual Global Investment ConferenceDate: September 8-10, 2019Company Presentation: Monday, September 9, 2019 at 4:40 pm (Eastern time) Location:  Lotte New York Palace Hotel, New […]

by

The cannabidiol marketplace is likely to witness significant RD investment in the pharmaceutical industry as a broad-spectrum pharmaceutical therapeutics. Multiple scientific studies have shown promising results of cannabidiol for its potential in the treatment of a number of diseases. Following which the Cannabidiol Market is marked by a considerable cannabidiol therapeutics getting FDA approval or […]

by